Please ensure Javascript is enabled for purposes of website accessibility

Why Intercept Pharmaceuticals Stock Got Crushed in March

By George Budwell – Apr 8, 2020 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Intercept's stock is ridiculously cheap after last month's sharp pullback.

What happened

Shares of the mid-cap biopharma Intercept Pharmaceuticals (ICPT 0.00%) fell by 31.5% during the month of March, according to data from S&P Global Market Intelligence. The drugmaker's shares hit the skids last month for two reasons:

  1. The biopharmaceutical space in general got walloped in March due to the coronavirus. Investors fled this area of the market due to fears over global supply chain issues, disruptions in ongoing clinical trials, and regulatory delays in both Europe and the United States. Intercept, for its part, couldn't escape this "man with a hammer" approach to biopharma stocks last month.  
  2. In late March, the U.S. Food and Drug Administration (FDA) announced that it would delay the advisory committee meeting for Intercept's nonalcoholic steatohepatitis (NASH) drug candidate, obeticholic acid (brand name: Ocaliva). The meeting was originally slated for April 22, but it will now be held on June 9 due to the COVID-19 pandemic. 
A doctor holding his hand out with a holographic image of a liver hovering above it.

Image source: Getty Images.

So what

Intercept has a real shot at becoming the first company to bring a NASH drug to market. That said, there are dozens of other drugs racing to hit the market as well. So any delay -- like the one announced last month -- could cost the company a significant amount in future revenue. Ocaliva, after all, may have serious trouble fending off would-be competitors in a crowded marketplace.

Now what

While Ocaliva does have some minor safety issues in the NASH setting, these safety concerns shouldn't ultimately derail its commercial launch. Intercept should thus end up with the first approved NASH drug, barring an unexpected turn of events. This mid-cap biopharma stock, in turn, may be worth a serious look by risk-tolerant investors, especially after last month's sharp pullback. 

George Budwell owns shares of Intercept Pharmaceuticals. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$15.24 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.